Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BP1003 makes a strong initial showing
June 2019
SHARING OPTIONS:

HOUSTON—Preclinical data from BP1003, which was presented at this year’s AACR annual meeting, shows that the compound has potential for treating pancreatic cancer, non-small cell lung cancer and acute myelogenous leukemia (AML), Bio-Path Holdings Inc. reported recently. BP1003 was found to inhibit cell viability and STAT3 protein expression in AML cells. STAT3 is aberrantly active in cancer cells and plays a role in cancer proliferation and angiogenesis, and also is a key culprit in tumor immune evasion. In ex-vivo testing, combining BP1003 with gemcitabine led to increased efficacy in a subset of patient-derived xenografts (PDX). In an in-vivo study of PDAC PDX models, BP1003 with gemcitabine resulted in tumor regression during the 28-day treatment period, and the anticancer activity was maintained for a further 21 days, even after treatment cessation. In addition, BP1003 was found to successfully penetrate the stroma into pancreatic tumors in preclinical models.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.